Recent Finacing
Recent Raise
Phico Therapeutics develops SASPject, a bacteriophage-based platform delivering small acid‑soluble spore protein genes to inactivate bacterial DNA, advancing systemic antibacterial candidates against P. aeruginosa, Klebsiella, and E. coli.
